Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Summary

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Timeline

Start

2007-11

Primary completion

—

Completion

—

Drugs

Indications